These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Toward Defining Primary and Secondary Nonresponse in Rheumatoid Arthritis Patients Treated with Anti-TNF: Results from the BioTRAC and OBRI Registries. Keystone EC; Rampakakis E; Movahedi M; Cesta A; Stutz M; Sampalis JS; Nantel F; Maslova K; Bombardier C J Rheumatol; 2020 Apr; 47(4):510-517. PubMed ID: 31263067 [TBL] [Abstract][Full Text] [Related]
43. Patient perspectives on achieving treat-to-target goals: a critical examination of patient-reported outcomes. Curtis JR; Shan Y; Harrold L; Zhang J; Greenberg JD; Reed GW Arthritis Care Res (Hoboken); 2013 Oct; 65(10):1707-12. PubMed ID: 23740824 [TBL] [Abstract][Full Text] [Related]
44. Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany. Lyu R; Govoni M; Ding Q; Black CM; Kachroo S; Fan T; Ogbonnaya A; Donga P; Hill J; Makin C Rheumatol Int; 2016 Jan; 36(1):143-53. PubMed ID: 26314368 [TBL] [Abstract][Full Text] [Related]
45. Not all moderate disease is the same - Identification of disability trajectories among patients with rheumatoid arthritis and moderate disease activity. Pan Y; Norton S; Gwinnutt JM; Kearsley-Fleet L; Symmons DPM; Lunt M; Young A; ; Hyrich KL; Verstappen SMM PLoS One; 2019; 14(5):e0215999. PubMed ID: 31107887 [TBL] [Abstract][Full Text] [Related]
46. Induction of response with etanercept-methotrexate therapy in patients with moderately active rheumatoid arthritis in Central and Eastern Europe in the PRESERVE study. Pavelka K; Szekanecz Z; Damjanov N; Majdan M; Nasonov E; Mazurov V; Fabo T; Bananis E; Jones H; Szumski A; Tang B; Kotak S; Koenig AS; Vasilescu R Clin Rheumatol; 2013 Sep; 32(9):1275-81. PubMed ID: 23666316 [TBL] [Abstract][Full Text] [Related]
47. Are prognostic factors adequately selected to guide treatment decisions in patients with rheumatoid arthritis? A collaborative analysis from three observational cohorts. Baganz L; Richter A; Albrecht K; Schneider M; Burmester GR; Zink A; Strangfeld A Semin Arthritis Rheum; 2019 Jun; 48(6):976-982. PubMed ID: 30316460 [TBL] [Abstract][Full Text] [Related]
48. Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA). Singh JA; Hossain A; Tanjong Ghogomu E; Mudano AS; Tugwell P; Wells GA Cochrane Database Syst Rev; 2016 Nov; 11(11):CD012437. PubMed ID: 27855242 [TBL] [Abstract][Full Text] [Related]
49. Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in Japan. Takeuchi T; Matsubara T; Ohta S; Mukai M; Amano K; Tohma S; Tanaka Y; Yamanaka H; Miyasaka N Rheumatology (Oxford); 2015 Apr; 54(4):683-91. PubMed ID: 25257039 [TBL] [Abstract][Full Text] [Related]
50. Differential influence of Clinical Disease Activity Index components based on disease state in rheumatoid arthritis patients: real-world results from the Ontario Best Practices Research Initiative. Keystone E; Movahedi M; Cesta A; Bombardier C; Sampalis JS; Rampakakis E Clin Exp Rheumatol; 2022 Nov; 40(11):2147-2152. PubMed ID: 35383561 [TBL] [Abstract][Full Text] [Related]
51. The frequency of remission and low disease activity in patients with rheumatoid arthritis, and their ability to identify people with low disability and normal quality of life. Scott IC; Ibrahim F; Panayi G; Cope AP; Garrood T; Vincent A; Scott DL; Kirkham B; Semin Arthritis Rheum; 2019 Aug; 49(1):20-26. PubMed ID: 30685064 [TBL] [Abstract][Full Text] [Related]
52. Thresholds in disease activity for switching biologics in rheumatoid arthritis patients: experience from a large U.S. cohort. Zhang J; Shan Y; Reed G; Kremer J; Greenberg JD; Baumgartner S; Curtis JR Arthritis Care Res (Hoboken); 2011 Dec; 63(12):1672-9. PubMed ID: 21954144 [TBL] [Abstract][Full Text] [Related]
53. Effect of Fatigue, Older Age, Higher Body Mass Index, and Female Sex on Disability in Early Rheumatoid Arthritis in the Treatment-to-Target Era. Twigg S; Hensor EMA; Freeston J; Tan AL; Emery P; Tennant A; Morgan AW; Arthritis Care Res (Hoboken); 2018 Mar; 70(3):361-368. PubMed ID: 28511291 [TBL] [Abstract][Full Text] [Related]
54. No predictive effect of body mass index on clinical response in patients with rheumatoid arthritis after 24 weeks of biological disease-modifying antirheumatic drugs: a single-center study. Kim SK; Choe JY; Park SH; Lee H Clin Rheumatol; 2016 May; 35(5):1129-36. PubMed ID: 26932795 [TBL] [Abstract][Full Text] [Related]
55. Older age at rheumatoid arthritis onset and comorbidities correlate with less Health Assessment Questionnaire-Disability Index and Clinical Disease Activity Index response to etanercept in the RADIUS 2 registry. Martin WJ; Shim M; Paulus HE; Chaudhari S; Feng J; Elashoff D; Hahn TJ; Ranganath VK; J Clin Rheumatol; 2014 Sep; 20(6):301-5. PubMed ID: 25160011 [TBL] [Abstract][Full Text] [Related]
56. Clinical predictors of remission and low disease activity in Latin American early rheumatoid arthritis: data from the GLADAR cohort. Gamboa-Cárdenas RV; Ugarte-Gil MF; Loreto M; Sacnun MP; Saurit V; Cardiel MH; Soriano ER; Pisoni C; Galarza-Maldonado CM; Rios C; Radominski SC; Castelar-Pinheiro GDR; Bianchi WA; Appenzeller S; da Silveira IG; de Freitas Zerbini CA; Caballero-Uribe CV; Rojas-Villarraga A; Guibert-Toledano M; Ballesteros F; Montufar R; Vázquez-Mellado J; Esquivel-Valerio J; De La Torre IG; Barile-Fabris LA; Palezuelos FI; Andrade-Ortega L; Monge P; Teijeiro R; Achurra-Castillo ÁF; Esteva Spinetti MH; Alarcón GS; Pons-Estel BA Clin Rheumatol; 2019 Oct; 38(10):2737-2746. PubMed ID: 31161486 [TBL] [Abstract][Full Text] [Related]
57. Drug survival of adalimumab in patients with rheumatoid arthritis over 10 years in the real-world settings: high rate remission together with normal function ability. Iannone F; Sinigaglia L; Favalli EG; Sarzi-Puttini P; Atzeni F; Caporali R; Codullo V; Ferraccioli G; Gremese E; Carletto A; Giollo A; Govoni M; Bergossi F; Galeazzi M; Cantarini L; Salaffi F; Di Carlo M; Bazzani C; Pellerito R; Sebastiani M; Ramonda R; Lapadula G Clin Rheumatol; 2016 Nov; 35(11):2649-2656. PubMed ID: 27418051 [TBL] [Abstract][Full Text] [Related]
58. Gain in quality-adjusted life-years in patients with rheumatoid arthritis during 1 year of biological therapy: a prospective study in clinical practice. Linde L; Sørensen J; Østergaard M; Hetland ML J Rheumatol; 2013 Sep; 40(9):1479-86. PubMed ID: 23818719 [TBL] [Abstract][Full Text] [Related]
59. Effect of initiating biologics compared to intensifying conventional DMARDs on clinical and MRI outcomes in established rheumatoid arthritis patients in clinical remission: Secondary analyses of the IMAGINE-RA trial. Møller-Bisgaard S; Hørslev-Petersen K; Ejbjerg B; Hetland ML; Christensen R; Ørnbjerg LM; Glinatsi D; Møller JM; Boesen M; Stengaard-Pedersen K; Madsen OR; Jensen B; Villadsen JA; Hauge EM; Bennett P; Hendricks O; Asmussen K; Kowalski M; Lindegaard H; Bliddal H; Krogh NS; Ellingsen T; Nielsen AH; Larsen L; Jurik AG; Thomsen HS; Østergaard M Scand J Rheumatol; 2022 Jul; 51(4):268-278. PubMed ID: 34474649 [TBL] [Abstract][Full Text] [Related]
60. Predictors of patient decision to discontinue anti-rheumatic medication in patients with rheumatoid arthritis: results from the Ontario best practices research initiative. Ahluwalia V; Rampakakis E; Movahedi M; Cesta A; Li X; Sampalis JS; Bombardier C Clin Rheumatol; 2017 Nov; 36(11):2421-2430. PubMed ID: 28879413 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]